Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 8월 20

Galmed Pharmaceuticals Ltd

GLMDNASDAQ
Trade with Public
Trade with Public
$4.52
-0.25-5.24%
마지막 업데이트: Aug 20, 1:51 PM
PRO
변동 이유?:Galmed Pharmaceuticals shares are trading higher after the company's subsid...
주식 분할: Galmed Pharmaceuticals Ltd는 최근 분할했습니다. Wednesday, August 19, 2026 비율로 1:8
개요뉴스실적 전망목표가재무심리비교주식 보고서

Galmed Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Galmed Pharmaceuticals (GLMD).

Analyst Consensus — 1 Analysts

1Hold
# Analysts1

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Apr 4, 2025Maxim GroupNaz RahmanDowngradeBuy→Hold—

Analyst Ratings News

PRO
Maxim Group Downgrades Galmed Pharmaceuticals to Hold

Maxim Group analyst Naz Rahman downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023

Benzinga Insights

PRO
Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

Maxim Group analyst Jason McCarthy upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Hold to Buy and announces $4 price target.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

 
Benzinga Insights

PRO
Maxim Group Downgrades Galmed Pharmaceuticals to Hold

Maxim Group analyst Jason McCarthy downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold.
Benzinga Newsdesk

PRO
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Canaccord Genuity analyst Edward Nash downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold and lowers the price target from $5 to $1.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved